PriceTargets.com logo

Life Science REIT - LABS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: GBX 46.50
  • Forecasted Upside: 21.09%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 38.40 As of 11/21/2024 11:03 AM ET
▼ -1.3 (-3.27%)

This chart shows the closing price for LABS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Life Science REIT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LABS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LABS

Analyst Price Target is GBX 46.50
▲ +21.09% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Life Science REIT in the last 3 months. The average price target is GBX 46.50, with a high forecast of GBX 57 and a low forecast of GBX 36. The average price target represents a 21.09% upside from the last price of GBX 38.40.

This chart shows the closing price for LABS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Life Science REIT. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/3/2024Berenberg BankReiterated RatingBuyGBX 57
9/26/2024Shore CapitalReiterated RatingBuy
8/30/2024Jefferies Financial GroupLower TargetHoldGBX 45 ➝ GBX 36
2/9/2024Berenberg BankReiterated RatingBuyGBX 79
3/27/2023Jefferies Financial GroupReiterated RatingBuyGBX 114
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Life Science REIT logo
Life Science REIT plc (the Company) is a closed-ended Real Estate Investment Trust (REIT) incorporated in England and Wales on 27 July 2021. The Company began trading on 19 November 2021 and its shares are admitted to trading on the Premium Listing Segment of the Main Market of the London Stock Exchange. The registered office of the Company is located at 6th Floor, 65 Gresham Street, London, EC2V 7NQ.
Read More

Today's Range

Now: GBX 38.40
Low: 38.30
High: 40.40

50 Day Range

MA: GBX 38.76
Low: 31.50
High: 42.60

52 Week Range

Now: GBX 38.40
Low: 31.30
High: 66.80

Volume

397,729 shs

Average Volume

1,024,910 shs

Market Capitalization

£134.40 million

P/E Ratio

N/A

Dividend Yield

6.21%

Beta

0.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Life Science REIT?

The following Wall Street research analysts have issued reports on Life Science REIT in the last year: Berenberg Bank, Jefferies Financial Group Inc., and Shore Capital.
View the latest analyst ratings for LABS.

What is the current price target for Life Science REIT?

0 Wall Street analysts have set twelve-month price targets for Life Science REIT in the last year. Their average twelve-month price target is GBX 46.50, suggesting a possible upside of 21.4%. Berenberg Bank has the highest price target set, predicting LABS will reach GBX 57 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of GBX 36 for Life Science REIT in the next year.
View the latest price targets for LABS.

What is the current consensus analyst rating for Life Science REIT?

Life Science REIT currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LABS.

What other companies compete with Life Science REIT?

Other companies that are similar to Life Science REIT include Target Healthcare REIT, Impact Healthcare REIT, Medicx Fund, Primary Health Properties and Assura. Learn More about companies similar to Life Science REIT.

How do I contact Life Science REIT's investor relations team?

Life Science REIT's physical mailing address is Beaufort House, 51 New North Road, Exeter EX4 4EP, United Kingdom, . The company's listed phone number is 44-20-7945-9566. The official website for Life Science REIT is www.lifesciencereit.co.uk. Learn More about contacing Life Science REIT investor relations.